Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 2 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Sep 22, 2025 · Source: ClinicalTrials.gov
The study is currently accepting participants.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Colorado, Denver
- Interventions being studied
- Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: sputum cytology; Procedure: biopsy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Diagnosis of extensive and severe dysplasia of the respiratory epithelium
- Those without dysplasia of the respiratory epithelium
- Recruited from the SPORE Tissue Procurement Screening Project or by private or academic physicians (for patients with moderate or severe dysplasia)
- Survived 1 or more aerodigestive system carcinoma for ≥ 1 year
- Completely resected stage I non-small cell cancer
- Undergoing any of the following procedures:
- Routine panendoscopy for patients with head and neck cancer
- Resection of a bronchogenic carcinoma
- Bronchoscopy for diagnosis or staging of suspected lung cancer
- Subsequent bronchoscopy for surveillance or monitoring of response to endobronchial treatment in patients with prior high-grade dysplasia or worse
- No asthma
- No lung disease
- No respiratory illness within the past 2 weeks Patients suspected of or at risk for neoplastic lung disease who are undergoing a bronchoscopy in which differential diagnostic considerations may include multiple other etiologies such as infection and other processes.
- Patients without dysplasia will be: patients undergoing clinically indicated bronchoscopy for conditions other than suspected lung cancer. PATIENT CHARACTERISTICS:
- No clinically apparent bleeding diathesis
- No known bleeding disorder
- No anginal
- No clinically active coronary artery disease
- No multifocal premature ventricular contractions
- No poorly controlled congestive heart failure
- No myocardial infarction within the past 6 weeks
- No cardiac dysrhythmia that is potentially life threatening
- Well-controlled atrial fibrillation or rare (\< 2/min) premature ventricular contractions allowed
- No ventricular tachycardia or supraventricular tachycardia with a rapid ventricular response
- No other serious medical condition that would preclude a patient from undergoing a bronchoscopy
- No acute bronchitis or pneumonia within the past 8 weeks except when clinically proven as a possible result of lung cancer
- No hypoxemia (i.e., \< 90% saturation with supplemental oxygen) before bronchoscopy PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Colorado Cancer Center at UC Health Sciences CenterAurora, Colorado
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 22, 2025. Always confirm current availability with the study team.